About the job
Join Revolution Medicines, a pioneering clinical-stage precision oncology firm dedicated to advancing innovative targeted therapies aimed at inhibiting key targets in RAS-dependent cancers. Our extensive R&D pipeline features RAS(ON) Inhibitors designed to target various oncogenic RAS protein variants, alongside RAS Companion Inhibitors tailored for combination treatment regimens. As a valued member of our talented team, you will engage in a passionate mission to support patients battling cancers with mutations in the RAS signaling pathway.
About the Position:
We are seeking a DMPK Scientist to play a pivotal role within our Drug Metabolism and Pharmacokinetics (DMPK) team under the Nonclinical Development and Clinical Pharmacology (NDCP) department. In this role, you will:
Design and conduct in vitro and in vivo metabolite identification studies utilizing liver microsomes, hepatocytes, recombinant enzymes, and biological samples (blood, plasma, tissue, urine, bile, etc.), performing metabolite profiling and structural elucidation.
Characterize significant, unique, or disproportionate metabolites to support candidate selection, MIST (Metabolites in Safety Testing) analysis, and regulatory strategies concerning metabolites.
Design and perform mechanistic studies to elucidate metabolic pathways and enzyme kinetics; collaborate with pharmaceutical product teams to characterize drug degradation products and impurities.
Develop and implement PBPK models to predict human drug-drug interaction (DDI) risk using preclinical datasets; assist in regulatory discussions related to PBPK-based DDI modeling strategies.
Author and review DMPK sections of regulatory submissions while addressing inquiries from regulatory agencies.
Foster and maintain robust collaborative partnerships across various functional areas including Discovery research, Clinical Pharmacology, Medicinal Chemistry, Pharmaceutical Development, Toxicology, and Translational Research.

